Treatment of human enterovirus infections

Antiviral Research

Volumn 38, Issue 1, 1998, Pages 1-14

  Rotbart, Harley A ^a   O'Connell, John F ^b,d   McKinlay, Mark A ^c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c ViroPharma   (United States)

^d PFIZER INC   (United States)

Author keywords

Aseptic meningitis; Coxsackieviruses; Enteroviruses; Summer flu; Viral syndrome

Indexed keywords

5 [5 [2,6 DICHLORO 4 (4,5 DIHYDRO 2 OXAZOLYL)PHENOXY]PENTYL] 3 METHYLISOXAZOLE; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; CAPSID PROTEIN; DISOXARIL; ENVIROXIME; INTERFERON; PIRODAVIR; PROTEINASE INHIBITOR; VIRUS VACCINE;

ANTIVIRAL ACTIVITY; ASEPTIC MENINGITIS; COXSACKIE VIRUS; DRUG STRUCTURE; ECHO VIRUS; ENTEROVIRUS; HUMAN; IN VITRO STUDY; MENINGOENCEPHALITIS; MORBIDITY; MORTALITY; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; REVIEW; RHINOVIRUS; SEROTYPE; SUMMER;

COXSACKIEVIRUS; ECHOVIRUS; ENTEROVIRUS; MIRIDAE; POLIOVIRUS; RHINOVIRUS; RNA VIRUSES;

EID: 0032054051     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(97)00068-5     Document Type: Article

References (106)

1. Abzug, M.J., Keyserling, H.L., Lee, M.L., Levin, M.J., Rotbart, H.A., 1995. Neonatal enterovirus infection: virology, serology and effects of intravenous immune globulin. Clin. Infect. Dis. 20, 1201-1206.
2. Abzug, M.J., 1995. Perinatal enterovirus infections. In: Rotbart, H.A. (Ed.), Human Enterovirus Infections. ASM Press, Washington, DC, pp. 221-238.
3. Al-Nakib, W., Higgins, P.G., Barrow, G.I., Tyrrell, D.A.J., Andries, K., Bussche, G.V., Taylor, N., Janssen, P.A.J., 1989. Suppression of colds in human volunteers challenged with rhinovirus by a new synthetic drug (R 61837). Antimicrob. Agents Chemother. 33, 522-525.
4. Barrow, G.I., Higgins, P.G., Tyrrell, D.A.J., Andries, K., 1990. An appraisal of the efficacy of the antiviral R 61837 in rhinovirus infections in human volunteers. Antiviral Chem. Chemother. 5, 278-283.
5. Black, S., 1983. Treatment of overwhelming neonatal ECHO 5 virus infection with intravenous gamma globulin (abstract 314). In: Program and Abstracts of the 23rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Las Vegas). American Society for Microbiology, Washington, DC, p. 140.
6. Bultman, B.D., Eggers, H.J., Galle, J., Haferkamp, O., 1983. Age dependence of paralysis induced by echovirus type 9 in infant mice. J. Infect. Dis. 147, 999-1005.
7. Buontempo, P., Cox, S., Wright-Minogue, J., DeMartino, J., Skelton, A., Albin, R., Rozhon, E., Girijavallabhan, V., O'Connell, J.F., 1997. SCH 48973: a potent, broad spectrum antienterovirus compound. Antimicrob. Agents Chemother. 41, 1220-1225.
8. Capobianchi, M.R., Matteucci, D., Giovannetti, A., Soldaini, E., Bendinelli, M., Stanton, J.G., Dianzani, F., 1991. Role of interferon in lethality and lymphoid atrophy induced by coxsackievirus B3 infection in mice. Virol. Immunol. 5, 103-110.
9. CDC, 1996. Progress toward global eradication of poliomyelitis. MMWR 45, 565-568.
10. CDC, 1997a. Progress toward poliomyelitis eradication -Africa, 1996. MMWR 46, 321-325.
11. CDC, 1997b. Progress toward poliomyelitis eradication -Europe and central Asian republics. MMWR 46, 994-1000.
12. Chebath, J., Benech, P., 1987. Constitutive expression of (2′-5′) oligo A synthetase confers resistance to picornavirus infection. Nature 330, 587-588.
13. Cherry, J.D., 1987. Enteroviruses: polioviruses (poliomyelitis), coxsackieviruses, echoviruses, and enteroviruses. In: Feigin, R.D., Cherry, J.D. (Eds.), Textbook of Pediatric Infectious Diseases, 2nd ed. Saunders, Philadelphia, pp. 1729-1841.
14. Chonmaitree, T., Baron, S., 1991. Bacteria and viruses induce production of interferon in the cerebrospinal fluid of children with acute meningitis: a study of 57 cases and review. Rev. Infect. Dis. 13, 1061-1065.
15. Chonmaitree, T., Ford, C., Sanders, C., Lucia, H.L., 1988. Comparison of cell cultures for rapid isolation of enteroviruses. J. Clin. Microbiol. 26, 2576-2580.
16. Cox, S., Bunotempo, P., Wright-Minogue, J., DeMartino, J., Skelton, A., Ferrari, E., Schwartz, J., Rozhon, E., Linn, C., Girijavallabhan, V., O'Connell, J.F., 1996. Antipicornavirus activity of SCH 47802 and analogues: in vitro and in vivo studies. Antiviral Res. 32, 71-79.
17. Dagan, R., 1996. Nonpolio enteroviruses and the febrile young infant: epidemiologic, clinical and diagnostic aspects. Pediatr. Infect. Dis. J. 15, 67-71.
18. Dagan, R., Menegus, M.A., 1986. A combination of four cell types for rapid detection of enteroviruses in clinical specimens. J. Med. Virol. 19, 219-228.
19. Dalakas, M.C., 1995. Enteroviruses and human neuromuscular diseases. In: Rotbart, H.A. (Ed.), Human Enteroviruses Infections. ASM Press, Washington, DC, pp. 387-398.
20. Dalakas, M.C., Sever, J.L., Madden, D.L., Papadopoulos, N.M., Shekarchi, I.C., Albrecht, P., Krezlewicz, A., 1984. Late postpoliomyelitis muscular atrophy: clinical, virologie, and immunologic studies. Rev. Infect. Dis. 6, S562-567.
21. DeLong, D.C., Nelson, J.D., Wu, E., Warren, B., Wikel, J., Templeton, R.J., Dinner, A., 1978a. Virus inhibition studies with AR-36. III. Relative activity of syn and anti isomers (abstract 34) In: Program and Abstracts of the 18th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, DC.
22. DeLong, D.C., Nelson, J.D., Wu, C.Y.E., Warren, B., Wikel, J., Chamberlin, J., Montgomery, D., Paget, C.J., 1978b. Virus inhibition studies with AR-336. I. Tissue culture activity (abstract S-128) In: Abstracts of the 78th Annual Meeting of the American Society for Microbiology 1978. American Society for Microbiology, Washington, DC, p. 234.
23. Douglas, R.M., Moore, B.W., Miles, H.B., Davies, L.M., Graham, N., Ryan, P., Worswick, D., Albricht, J., 1986. Prophylactic efficacy of intranasal alpha A2-interferon against rhinovirus infections in the family setting. N. Engl. J. Med. 314, 65-70.
24. Eggers, H.J., Koch, M.A., Furst, A., Daves, G.D. Jr., Wilczynski, J.J., Folkers, K., 1970. Rhodamine: a selective inhibitor of the multiplication of echovirus 12. Science 167, 294-297.
25. Enders, J.F., Weller, T.H., Robbins, F.C., 1949. Cultivation of the Lansing strain of poliomyelitis virus in cultures of various human embryonic tissues. Science 109, 850-887.
26. Fox, M.P., McKinlay, M.A., Diana, G.D., Dutko, F.J., 1991. Binding affinities of structurally related human rhinovirus capsid-binding compounds are related to their activities against human rhinovirus type 14. Antimicrob. Agents Chemother. 35, 1040-1047.
27. Fromtling, R.A., Castaner, J., 1997. VP-63843. Drugs Future 22, 40-44.
28. Geniteau-Legendre, M., Forestier, F., Quero, A.M., German, A., 1987. Role of interferon, antibodies and macrophages in the protective effect of Corynebacterium parvum on encephalomyocarditis virus-induced disease in mice. Antiviral Res. 7, 161-167.
29. Greenberg, S.B., Harmon, M.W., Couch, R.B., Johnson, P.E., Wilson, S.Z., Dacso, C.C., Bloom, K., Quarles, J., 1982. Prophylactic effect of low doses of human leukocyte interferon against infection with rhinovirus. J. Infect. Dis. 145, 542-546.
30. Grist, N.R., Bell, E.J., 1984. Paralytic poliomyelitis and non-polio enteroviruses: studies in Scotland. Rev. Infect. Dis. 6, S385-S386.
31. Groarke, J.M., McKinlay, M.A., Dutko, F.J., Pevear, D.C., 1995. Coxsackievirus B3 mutants resistant to WIN 63843 are attenuated for virulence in mice: molecular analysis of the drug resistant phenotype. Antiviral Res. 26, A300.
32. Haller, A.A., Semier, B.L., 1995. Translation and host cell shutoff. In: Rotbart, H.A. (Ed.), Human Enterovirus Infections. ASM Press, Washington, DC, pp. 113-133.
33. Hayden, F., Albrecht, J.K., Kaiser, D.L., Gwaltney, J.M., 1986. Prevention of natural colds by contact prophylaxis with intranasal alpha 2-interferon. N. Engl. J. Med. 314, 71-75.
34. Hayden, F.G., Gwaltney, J.M. Jr., 1982. Prophylactic activity of intranasal enviroxime against experimentally induced rhinovirus type 39 infection. Antimicrob. Agents Chemother. 21, 892-897.
35. Hayden, F., Gwaltney, J.M., 1983. Intranasal interferon alpha2 for prevention of rhinovirus infection and illness. J. Infect. Dis. 148, 543-550.
36. Hayden, F., Gwaltney, J.M., 1984. Intranasal interferon-a2 treatment of experimental rhinovirus colds. J. Infect. Dis. 150, 174-180.
37. Hayden, F.G., Andries, A., Janssen, P.A.J., 1992. Safety and efficacy of intranasal pirodavir (R 77975) in experimental rhinovirus infection. Antimicrob. Agents Chemother. 36, 727-732.
38. Heinz, B.A., 1990. Escape mutant analysis of a drug-binding site can be used to map functions in the rhinovirus capsid. In: Laver, W.G., Air, G.A. (Eds.), Use of X-Ray Crystallography in the Design of Antiviral Agents. Academic Press, San Diego, CA, pp. 173-186.
39. Heinz, B.A., Vance, L.M., 1995. The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus. J. Virol. 69, 4189-4197.
40. Heinz, B.A., Rueckert, R.R., Shepard, D.A., Dutko, F.J., McKinlay, M.A., Fancher, M., Rossmann, M.G., Badger, J., Smith, T.J., 1989. Genetic and molecular analysis of spontaneous mutants of human rhinovirus 14 that are resistant to an antiviral compound. J. Virol. 63, 2476-2485.
41. Hellen, C.U.T., Wimmer, E., 1995. Enterovirus genetics. In: Rotbart, H.A. (Ed.), Human Enterovirus Infections. ASM Press, Washington, DC, pp. 25-72.
42. Hogle, J.M., Chow, M., Filman, D.J., 1985. Three-dimensional structure of poliovirus at 2.9 A resolution. Science. 229, 1358-1365.
43. Ichimura, H., Shimase, K., Tamura, L, Kaneto, E., Kurimura, O., Aramitsu, Y., Kurimura, T., 1985. Neutralizing antibody and interferon-alpha in cerebrospinal fluids and sera of acute aseptic meningitis. J. Med. Virol. 15, 231-237.
44. Ishitsuka, H., Ohsawa, C., Ohiwa, T., Umeda, I., Suhara, Y., 1982. Antipicornavirus flavone Ro 09-0179. Antimicrob. Agents Chemother. 22, 611-616.
45. Jantausch, B.A., Luban, N.L.C., Duffy, L., Rodriquez, W.J., 1995. Maternal plasma transfusion in the treatment of disseminated neonatal echovirus 11 infection. Pediatr. Infect. Dis. J. 14, 154-155.
46. Johnston, J.M., Overall, J.C. Jr., 1989. Intravenous immunoglobulin in disseminated neonatal echovirus II infection. Pediatr. Infect. Dis. J. 8, 254-256.
47. Johnson, K.L., Sarnow, P., 1995. Viral DNA synthesis. In: Rotbart, H.A. (Ed.), Human Enterovirus Infections. ASM Press, Washington, DC, pp. 95-112.
48. Jubelt, B., Wilson, A.K., Ronka, S.I., Guidinger, P.I., McKinlay, M.A., 1989. Clearance of a persistent human enterovirus infection of the mouse central nervous system by the antiviral agent disoxaril. J. Infect. Dis. 159, 866-871.
49. Kandolf, R., Canu, A., Hofschneider, P.H., 1985. Coxsackie B3 virus can replicate in cultured human foetal heart cells and is inhibited by interferon. J. Mol. Cell. Cardiol. 17, 167-181.
50. Kenny, M.T., Dulworth, J.K., Barger, T.M., Daniel, J.K., 1987. Antipicornavirus activity of some diaryl methanes and aralkylaminopyridines. Antiviral Res. 7, 87-97.
51. Kishimoto, C., Crumpacker, C.S., Abelmann, W.H., 1988. Prevention of murine coxsackie B3 viral myocarditis and associated lymphoid organ atrophy with recombinant human leucocyte interferon alpha A/D. Cardiovasc. Res. 22, 732-738.
52. Klingel, K., Stephan, S., Suater, M., ZeIl, R., McManus, B.M., Bultman, B.D., Kandolf, R., 1996. Pathogenesis of murine enterovirus myocarditis: virus dissemination and immune cell targets. J. Virol. 70, 8888-8895.
53. Langford, M.P., Carr, D.J., Yin-Murphy, M., 1985. Activity of arildone with or without interferon against acute hemorrhagic conjunctivitis viruses in cell culture. Antimicrob. Agents Chemother. 28, 578-580.
54. Langford, M.P., Kadi, R.M., Ganley, J.P., Yin-Murphy, M., 1988. Inhibition of epidemic isolates of coxsackie virus type A24 by recombinant and natural interferon alpha and interferon beta. Intervirology 29, 320-327.
55. Last-Barney, K.L., Marlin, S.D., Pal, K., Cahill-Feehan, C., McNally, E.J., Jeanfavre, D.D., Merluzzii, V.J., 1993. Method for detection of picornavirus capsid binders with soluble intracellular adhesion molecule 1. Antimicrob. Agents Chemother. 37, 1693-1695.
56. Lopez-Guerrero, J.A., Pimentel-Muinos, F.X., Fresno, M., Alonso, M.A., 1990. Role of soluble cytokines on the restricted replication of poliovirus in the monocytic U937 cell line. Virus Res. 16, 225-230.
57. McKinlay, M.A., Steinberg, B.A., 1986. Oral efficacy of WIN 51711 in mice infected with human poliovirus. Antimicrob. Agents Chemother. 29, 30-32.
58. McKinlay, M.A., Frank, J.A., Steinberg, B.A., 1986. Use of WIN 51711 to prevent echovirus type 9-induced paralysis in suckling mice. J. Infect. Dis. 154, 676-681.
59. McKinney, R.E., Katz, S.L., Wilfert, C.M., 1987. Chronic enteroviral meningoencephalitis in agammaglobulinemic patients. Rev. Infect. Dis. 9, 334-356.
60. Melnick, J.L., 1990. Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses. In: Fields, B.N., Knipe, D.M. (Eds.), Virology. Raven Press, New York, pp. 549-605.
61. Melnick, J.L., Godman, G.C., 1951. Pathogenesis of coxsackievirus infection. Multiplication of virus and evolution of muscle lesions in mice. J. Exp. Med. 93, 247-266.
62. Melnick, J.L., Rennick, V., 1980. Infectivity titers of enteroviruses as found in human stools. J. Med. Virol. 5, 205-220.
63. Merigan, T., Reed, S., Hall, T., Tyrrell, D., 1973. Inhibition of respiratory virus infection by locally applied interferon. Lancet i, 536-567.
64. Miller, M.J., 1997. Viral taxonomy. Clin. Infect. Dis. 25, 18-19.
65. Miller, F.D., Monto, A.S., DeLong, D.C., Exelby, A., Bryan, E.R., Srivastava, S., 1985. Controlled trial of enviroxime against natural rhinovirus infections in a community. Antimicrob. Agents Chemother. 27, 102-106.
66. Modlin, J.F., Polk, B.F., Horton, P., Etkind, P., Crane, E., Spiliotes, A., 1981. Perinatal echovirus infection; risk of transmission during a community outbreak. N. Engl. J. Med. 305, 368-371.
67. Monto, A.S., Schwartz, S.A., Albrecht, J.K., 1989. Ineffectiveness of postexposure prophylaxis of rhinovirus infection with low-dose intranasal alpha 2b interferon in families. Antimicrob. Agents Chemother. 33, 387-390.
68. Muir, P., Nicholson, F., Spencer, G.T., Ajetunmobi, J.F., Starkey, W.G., Khan, M., Archard, L.C., Cairns, N.J., Anderson, V.E., Leigh, P.N., Howard, R.S., Banatvala, J.E., 1996. Enterovirus infection of the central nervous system of humans: lack of association with chronic neurological disease. J. Gen. Virol. 77, 1469-1476.
69. Ninomiya, Y., Aoyama, M., Umeda, I., Suhara, Y., Ishitsuka, H., 1985. Comparative studies on the modes of action of the antirhinovirus agents Ro 09-0410, Ro 09-0179, RMI 15,731, 4′6-dichloroflavan, and enviroxime. Antimicrob. Agents Chemother. 27, 595-599.
70. Ninomiya, Y., Shimma, N., Ishitsuka, H., 1990. Comparative studies on the mode of action of rhinovirus capsid binding agents, chalcone amides. Antiviral Res. 15, 61-74.
71. Okada, L, Matsumori, A., Matoba, Y., Tominaga, M., Yamada, T., Kowai, C., 1992. Combination treatment with ribavirin and interferon for coxsackievirus B3 replication. J. Lab. Clin. Med. 120, 569-573.
72. Otto, M.J., Fox, M.P., Fancher, M.J., Huhrt, M.F., Diana, G.D., McKinlay, M.A., 1985. In vitro activity of WIN 51711, a new broad-spectrum antipicornavirus drug. Antimicrob. Agents Chemother. 27, 883-886.
73. Patick, A.K., Ford, C., Binford, S., et al., 1997. Evaluation of the antiviral activity and cytotoxicity of peptide inhibitors of human rhinovirus 3C protease, a novel target for antiviral intervention. In: Abstracts of the 10th International Conference on Antiviral Research, Atlanta, GA, p. A75.
74. Pevear, D.C., Fancher, M.J., Felock, P.J., Rossmann, M.G., Miller, M.S., Diana, G.D., Treasurywala, A.M., McKinlay, M.A., Dutko, F.J., 1989. Conformational change in the floor of the human rhinovirus canyon blocks adsorption to HeLa cell receptors. J. Virol. 63, 2002-2007.
75. Pevear, D.C., Seipel, M.E., Pallansch, M., McKinlay, M.A., 1996. In vitro efficacy of VP 63843 against field isolates of non-polio enteroviruses. In: Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, p. 181.
76. Phillpotts, R.J., DeLong, D.C., Wallace, J., Jones, R.W., Reed, S.E., Tyrrell, D.A.J., 1981. The activity of enviroxime against rhinovirus infection in man. Lancet ii, 1342-1344.
77. Phillpotts, R.J., Wallace, J., Tyrrell, D.A.J., Tagart, V.B., 1983. Therapeutic activity of enviroxime against rhinovirus infection in volunteers. Antimicrob. Agents Chemother. 23, 671-675.
78. Pitkaranta, A., Linnavouri, K., Houi, T., 1991. Virus-induced interferon production in human leukocytes: a low responder to one virus can be a high responder to another virus. J. Interferon Res. 11, 17-23.
79. Racaniello, V.R., 1995. Early events in infection: receptor binding and cell entry. In: Rotbart, H.A. (Ed.), Human Enterovirus Infections. ASM Press, Washington, DC, pp. 73-93.
80. Rewers, M., Atkinson, M., 1995. The possible role of enteroviruses in diabetes mellitus. In: Rotbart, H.A. (Ed.), Human Enterovirus Infections. ASM Press, Washington, DC, pp. 353-385.
81. Rombaut, B., Vrijsen, R., Boeye, A., 1985. Comparison or arildone and 3-methylquercetin as stabilizers of poliovirus. Antiviral Res. Suppl. 1, 67-73.
82. Rombaut, B., Andries, K., Boeye, A., 1991. A comparison of WIN 51711 and R 78206 as stabilizers of poliovirus virions and procapsids. 72, 2153-2157.
83. Rotbart, H.A., 1995. Meningitis and encephalitis. In: Rotbart, H.A. (Ed.), Human Enterovirus Infections. ASM Press, Washington, DC, pp. 271-289.
84. Rotbart, H.A., Kirkegaard, K., 1992. Picornavirus pathogenesis: viral access, attachment, and entry into susceptible cells. Semin. Virol 3, 483-499.
85. Rotbart, H.A., Sawyer, M.H., Fast, S., Lewinski, C., Murphy, N., Keyser, E.F., Spadoro, J., Kao, S.Y., Loeffelholz, M., 1994. Diagnosis of enterovirus meningitis using the polymerase chain reaction with a colorimetric microwell detection assay. J. Clin. Microbiol. 32, 2590-2592.
86. Rotbart, H.A., Brennan, P.J., Fife, K.H., et al, 1996. Enterovirus meningitis in adults (abstract H41). 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, p. 170,
87. Rotbart, H.A., Ahmed, A., Hickey, S., Dagan, R., McCracken, G.H., Whitley, R.J., Modlin, J.F., Caxcino, M., O'Connell, J.F., Menegus, M.A., Blum, D., 1997. Diagnosis of enterovirus infection by polymerase chain reaction of multiple specimen types. Pediatr. Infect. Dis. J. 16, 409-411.
88. Rozhon, E., Cox, S., Buontempo, P., O'Connell, J., Slater, W., DeMartino, J., Schwartz, J., Miller, G., Arnolod, E., Zhang, A., Morrow, C., Jablonski, S., Pinto, P., Verace, R., Duelfer, T., Girijavallabhan, V., 1993. SCH 38057: a picornavirus capsid-binding molecule with antivial activity after the initial stage of viral uncoating. Antiviral Res. 21, 15-35.
89. Rueckert, R.R., 1990. Picornaviruses and their replication. In: Fields, B.N., Knipe, D.M. (Ed.), Virology. Raven Press, New York, pp. 507-548.
90. Samo, T.C., Greenberg, S.B., Couch, R.B., Quarles, J., Johnson, P.E., Hook, S., Harmon, M.W., 1983. Efficacy and tolerance of intranasal applied recombinant leukocyte A interferon in normal volunteers. J. Infect. Dis. 148, 535-542.
91. Sasaki, O., Karaki, T., Imanishi, J., 1986. Protective effect of interferon on infections with hand, foot and mouth disease virus in newborn mice. J. Infect. Dis. 153, 498-502.
92. Schiff, G.M., Sherwood, J.R., Young, E.C., Mason, L.J., 1992. Prophylactic efficacy of WIN 54954 in prevention of experimental human coxsackievirus A21 infection and illness. Antiviral Res. 17 (Suppl), 92.
93. Schiff, G.M., McKinlay, M.A., Sherwood, J.R., 1996. Oral efficacy of VP63843 in coxsackievirus A21 infected volunteers. In: Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, p. 171.
94. Strikas, R.A., Anderson, L.J., Parker, R.A., 1986. Temporal and geographic patterns of isolates of nonpolio enterovirus in the United States, 1970-1983. J. Infect. Dis. 153, 346-351.
95. Tebbe, M.J., Spitzer, W.A., Tang, J., 1997a. Oral bioavailability screening of the antirhinoviral vinyl acetylene benzimidazoles. In: Abstracts of the 10th International Conference on Antiviral Research, Atlanta, GA, p. A89.
96. Tebbe, M.J., Spitzer, W.A., Victor, S., et al, 1997b. Antirhinoviral vinyl acetylene benzimidazoles. In: Abstracts of the 10th International Conference on Antiviral Research, Atlanta, GA, p. A75.
97. Turner, R.B., Hayden, F.G., 1992. Efficacy or oral WIN 54954 for the prophylaxis of experimental rhino virus infection. Antiviral Res. 17 (Suppl), 92.
98. Turner, R.B., Dutko, F.J., Goldstein, N.H., Lockwood, G., Hayden, F.G., 1983. Efficacy of oral WIN 54954 for prophylaxis of experimental rhinovirus infection. Antimicrob. Agents Chermother. 37, 297-300.
99. Valduss, D., Murray, D.L., Kama, P., Lapour, K., Dyje, J., 1993. Use of intravenous immunoglobulin in twin neonates with disseminated coxsackie B1 infection. Clin. Pediatr. (Phila) 32, 561-563.
100. Webster, A.D.B., Rotbart, H.A., Warner, T., Rudge, P., Hyman, N., 1993. Diagnosis of enterovirus brain disease in hypogammaglobulinemic patients by polymerase chain reaction. Clin. Infect. Dis. 17, 657-661.
101. Wikel, J.H., Paget, C.J., DeLong, D.C., Nelson, J.D., Wu, C.Y.E., Paschal, J.W., Dinner, A., Templeton, R.J., Chaney, M.O., Jones, N.D., Chamberlin, J.W., 1980. Synthesis of syn and anti isomers of 6-[[(hydroxyimino) phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-I H-benzimidazol-2-amine. Inhibitors or rhinovirus multiplication. J. Med. Chem. 23, 368-372.
102. Wong, S.N., Tarn, A.Y., Ng, T.H., Ng, W.F., Tong, C.Y., Tang, T.S., 1989. Fatal coxsackie B1 virus infection in neonates. Pediatr. Infect. Dis. J. 8, 638-641.
103. Woods, M.G., Diana, G.D., Rogge, M.C., Otto, M.J., Dutko, F.J., McKinlay, M.A., 1989. In vitro and in vivo activities of WIN 54954, a new broad-spectrum antipicornavirus drug. Antimicrob. Agents Chemother. 33, 2069-2074.
104. Yasin, S.R., Al-Nakib, W., Tyrell, D.A.J., 1990. Pathogenecity for humans of human rhinovirus type 2 mutants resistant to or dependent on chalcone Ro 09-0410. Antimicrob. Agents Chemother. 34, 963-966.
105. Zhang, A., Nanni, R.G., Arnold, G.F., Oren, D.A., Li, T., Jacobo-Molkina, A., William, R.L., Kamer, G., Rubenstein, D.A., Li, Y., Rozhon, E., Cox, S., Bumotempo, P., O'Connell, J., Schwartz, J., Miller, G., Nash, C., Bauer, B., Versace, R., Ganguly, A., Girijavallabhan, V., Arnold, E., 1991. Structure of a complex of human rhinovirus 14 with a water soluble antiviral compound SCH 38057. J. Mol. Biol. 230, 857-867.
106. Zhang, A., Nanni, R.G., Oren, D.A., Rozhon, E.J., Arnold, E., 1992. Three-dimensional structure-activity relationships for antiviral agents that interact with picornavirus capsids. Semin. Virol. 3, 453-471.